ABSIAbsci Corporation
Price
+289%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market undecided.
We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low. We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of approximately $15 million per program, compared to an industry average of 4–6 years at a cost of greater than $50 million.
In the company’s own words · 10-K filed Mar 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Absci Corporation (ABSI) reported revenue of $318K in Q2 2026 (quarter ended Jun 30, 2026), down 46% from the same quarter a year earlier. That came with net loss of $33M. For the full year FY2025, revenue was $2.8M (−38% year on year) and net income −$115M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business.Earnings release · Form 8-K
- Jun 24, 2026On June 24, 2026, Absci Corporation issued a press release announcing Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201.Other event · Form 8-K
- Jun 24, 2026On June 24, 2026, Absci Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC (the “Underwriters”), relating to the issuance and sale of an aggregate of 13,495,277 shares …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.